CO2021016433A2 - Derivados heterocíclicos condensados - Google Patents
Derivados heterocíclicos condensadosInfo
- Publication number
- CO2021016433A2 CO2021016433A2 CONC2021/0016433A CO2021016433A CO2021016433A2 CO 2021016433 A2 CO2021016433 A2 CO 2021016433A2 CO 2021016433 A CO2021016433 A CO 2021016433A CO 2021016433 A2 CO2021016433 A2 CO 2021016433A2
- Authority
- CO
- Colombia
- Prior art keywords
- condensed heterocyclic
- heterocyclic derivatives
- compounds
- preparing
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933 | 2019-05-28 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021016433A2 true CO2021016433A2 (es) | 2021-12-10 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0016433A CO2021016433A2 (es) | 2019-05-28 | 2021-12-01 | Derivados heterocíclicos condensados |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| AR124222A1 (es) * | 2020-12-02 | 2023-03-01 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| US20240279227A1 (en) * | 2021-06-02 | 2024-08-22 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| AR126049A1 (es) | 2021-06-02 | 2023-09-06 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| WO2016109684A2 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| BR112021021564A2 (pt) * | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000230A (es) | 2022-05-31 |
| BR112021022889A2 (pt) | 2022-01-04 |
| MA56043A (fr) | 2022-04-06 |
| CL2021003155A1 (es) | 2022-07-22 |
| WO2020243135A1 (en) | 2020-12-03 |
| SG11202113167QA (en) | 2021-12-30 |
| CA3138168A1 (en) | 2020-12-03 |
| PH12021552974A1 (en) | 2022-07-11 |
| IL288322A (en) | 2022-01-01 |
| JP2022535734A (ja) | 2022-08-10 |
| CN113906028A (zh) | 2022-01-07 |
| KR20220012913A (ko) | 2022-02-04 |
| JOP20210313A1 (ar) | 2021-11-25 |
| BR112021022889A8 (pt) | 2024-03-05 |
| PE20220767A1 (es) | 2022-05-16 |
| MX2021014575A (es) | 2022-05-24 |
| CR20210666A (es) | 2022-03-11 |
| EP3976617B1 (en) | 2025-04-23 |
| EP3976617A1 (en) | 2022-04-06 |
| AU2020285718A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016433A2 (es) | Derivados heterocíclicos condensados | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| MX389697B (es) | Nuevos derivados de pirazolopirimidina. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2020002891A1 (es) | Nuevos derivados de quinolina | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY37182A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| MX393586B (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| CL2012001579A1 (es) | Compuestos derivados de (heterociclo-piperidina condensada)-(piperazinil) 1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1 alcanona, inhibidores de p75; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades neurodegenerativas, esquizofrenia, entre otras; compuesto intermediario. | |
| UY39793A (es) | Derivados heterocíclicos condensados | |
| UY39550A (es) | Derivados heterocíclicos condensados | |
| CL2011002625A1 (es) | Compuestos derivados de 3-(piridin-3-il-etinil)-piridina; preparaciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| ECSP21092791A (es) | Derivados heterocíclicos condensados | |
| UY39794A (es) | Derivados heterocíclicos condensados | |
| MX2021014581A (es) | Derivados heterociclicos condensados. | |
| MX2021014576A (es) | Derivados heterociclicos condensados como agentes antivirales. | |
| EA202193275A1 (ru) | Сочлененные гетероциклические производные | |
| BR112019014738A8 (pt) | Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula |